Begin main content

Programmed Death Ligand 1 (PD-L1) Testing for Pembrolizumab Effectiveness: Clinical Evidence

Last updated: May 30, 2016
Project Number: RA0848-000
Product Line: Rapid Response
Research Type: Other Diagnostics
Report Type: Reference List
Result type: Report

Question

  1. What is the accuracy of programmed death ligand 1 (PD-L1) diagnostic antibody assays?
  2. What is the clinical utility of PD-L1 testing in patients with non-small cell lung cancer?
  3. What is the effectiveness of programmed cell death protein 1 (PD-1)/PD-L1 checkpoint inhibitors for treating patients with non-small cell lung cancer with different levels of PD-L1 expression?

Key Message

Two health technology assessments, five systematic reviews, two randomized controlled trials, and two non-randomized studies were identified regarding the effectiveness of PD-1/PD-L1 checkpoint inhibitors for treating patients with non-small cell lung cancer with different levels of PD-L1 expression. No relevant studies were identified regarding the accuracy of diagnostic antibody assays or clinical utility of PD-L1 testing.